Sanai, Faisal M.
Al Khathlan, Abdullah
Al Fadhli, Ahmad
Jazzar, Ahmad S.
Hashim, Al Moutaz
Mansour, Eid
Abaalkhail, Faisal
Hasan, Fuad
Al Mudaiheem, Hajer
Al Quraishi, Huda
Bottomley, Juliana
Alswat, Khalid A.
Al Ghamdi, Mohammed
Farghaly, Mohamed
Fathy, Motaz
Awad, Nancy
Mohamed, Omneya
Kozma, Sam
Al-Hamoudi, Waleed
Al-jedai, Ahmed http://orcid.org/0000-0002-4730-9086
Funding for this research was provided by:
Gilead Sciences
Article History
Received: 9 December 2020
Accepted: 17 March 2021
First Online: 6 April 2021
Declarations
:
: Faisal M Sanai is a speaker for and consultant of Gilead Sciences, Intercept Pharmaceuticals and Pfizer; Ahmad Al Fadhli, [Details Awaited]; Eid Mansour is an employee of Gilead Sciences and owns shares in Gilead Sciences;; Fuad Hasan is a consultant and speaker for Gilead Sciences; Juliana Bottomley is the Director of Amygdala Limited and received funding from Gilead Sciences, as a consultant at the time of the study reporting; Nancy Awad and Omneya Mohamed are employees of IQVIA, Dubai and received funding from Gilead Sciences to conduct the study, analyses and reporting; Sam Kozma is an employee at Gilead Sciences; Ahmed Al-jedai is an employee of Ministry of Health,Saudi Arabia; Abdullah Al Khathlan, Ahmad S Jazzar, Al Moutaz Hashim, Faisal Abaalkhail, Hajer Al Mudaiheem, Huda Al Quraishi, Khalid A Alswat, Mohammed Al Ghamdi, Mohamed Farghaly, Motaz Fathy and Waleed Al-Hamoudi report no conflicts of interest related to this manuscript.
: Not applicable. This article does not contain any individual patient data.
: Not applicable. This article does not contain any studies with human subjects (or animals).